RGNX vs SLBT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RGNX · Regenxbio$7.62 ▲ 3.25%
SLBT · SL Science$0.94 ▲ 4.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RGNX -30.9%
- SLBT -91.0%
Head to head
| Metric | RGNX | SLBT |
|---|---|---|
| Price | $7.62 | $0.94 |
| Change today | ▲ 3.25% | ▲ 4.16% |
| Market cap | $503.85M | $525.71M |
| Return, 3 months | -26.9% | -66.9% |
| Return, year to date | -47.1% | -91.1% |
| Return, 1 year | -32.0% | -91.0% |
| P/E (TTM) | – | – |
| P/B | 3.4 | 78.1 |
| P/E percentile vs own 5y | 66th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +405.7% | -34.7% |
| Net profit growth (YoY) | +132.0% | -220.6% |
| Gross margin | 86.4% | 38.4% |
| Operating margin | -94.1% | -178.8% |
| Net margin | -112.6% | -178.4% |
| Return on equity | -137.6% | -74.9% |
| Analyst target vs. price | +181.5% | – |
| Analyst buy share | 82% | – |
| RSI (14) | 52 | 26 |
| 30-day volatility | 62.8% | 111.8% |
| Max drawdown, 1 year | -64.6% | -93.0% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLBT is the largest of the group by market value.
- RGNX has returned the most over the past year.
- RGNX is growing revenue fastest.
- RGNX keeps the most profit per dollar of sales.
- RGNX has been the calmest stock over the last 30 days.